Search clinical trials for: hzVSF-v13

Total 949 results

ImmuneMed, Inc.

Not yet recruiting

A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumatic Drug)

Moderate to Severe Rheumatoid Arthritis

Netherlands
ImmuneMed, Inc.

Completed

Safety, Tolerability, Pharmacokinetics of hzVSf-v13 in Healthy Adults (Intravenous and Subcutaneous Administration)

Healthy Volunteers

Australia
ImmuneMed, Inc.

Completed

Safety, Tolerability, Pharmacokinetic Characteristics of hzVSF-v13 in Healthy Male Volunteers

Healthy

Korea, Republic of
ImmuneMed, Inc.

Terminated

Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia

COVID-19

Korea, Republic of
ImmuneMed, Inc.

Completed

Efficacy and Safety of hzVSF-v13 in Patients With COVID-19 Pneumonia

COVID-19

Italy, Russian Federation
ImmuneMed, Inc.

Completed

Efficacy and Safety of hzVSF-v13 in Moderate to Severe Patients With COVID-19 Pneumonia

COVID-19

Indonesia
Takeda

Available

Expanded Access to TAK-113 for Adults With Metastatic Colorectal Cancer (mCRC)

Colorectal Cancer
Robert Bok, MD, PhD
National Cancer Institute (NCI)

Recruiting

Hyperpolarized Carbon-13 Alpha-ketoglutarate Imaging in IDH Mutant Glioma

Adult Gliomas, Mixed

United States
Robert Flavell, MD, PhD
Bristol-Myers Squibb; U.S. Army Medical Research Acquisition Activity

Recruiting

Magnetic Resonance (MR) Imaging With Hyperpolarized Bicarbonate (13C) to Measure Tissue pH in Prostate Cancer

Prostate Cancer | Localized Prostate Carcinoma

United States
Uppsala University

Unknown

A Comparative Study of Six Methods to Measure Human Contrast Vision

Methods to Measure Contrast Vision

Sweden
National Taiwan University Hospital

Recruiting

Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection

H. Pylori Infection

Taiwan
Hutchison Medipharma Limited

Completed

A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer (FALUCA)

NSCLC

China
Hutchison Medipharma Limited
Sun Yat-sen University; Fudan University

Completed

Study of Fruquintinib in Patients With Metastatic Colorectal Cancer

Colorectal Cancer

China
Hutchison Medipharma Limited
Fudan University; Eighty-One Hospital of People's Liberation Army

Completed

A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients （FRESCO) (FRESCO)

Colorectal Cancer

China
Hutchison Medipharma Limited
Shanghai Chest Hospital

Completed

A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
argenx

Completed

A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Formulation of ARGX-113 in Healthy Male Subjects

Bioavailability Study

Netherlands
Wake Forest University Health Sciences

Completed

Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies

Advanced Hematologic Malignancies

United States
Cornerstone Pharmaceuticals

Completed

A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies

Lymphoma | Metastatic Cancer | Advanced Cancer | Solid Tumors | Advanced Malignancies

United States, Canada
Cliniques universitaires Saint-Luc- Université...

Unknown

Investigating Project of the Functional C13 Test "Pilot Study" (PIL001)

Disorder of the Urea Cycle

Belgium
Hôpital Européen Marseille
Aix Marseille Université

Terminated

Response of the Autonomic Nervous System to Auricular Stimulation of the Vagus Nerve (x) (AURIX)

Vasoconstriction Disorder of Extremities

France
Mitsubishi Tanabe Pharma Corporation

Completed

Pharmacokinetic/Pharmacodynamic Study of MP-513 With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Sichuan Clover Biopharmaceuticals, Inc.

Completed

A Phase I Study Evaluating SCB-313(Recombinant Human TRAIL-Trimer Fusion Protein) for the Treatment of Malignant Pleural Effusion

Malignant Pleural Effusion

China
Javier Villaneuva-Meyer, MD
National Institute for Biomedical Imaging and Bioengineering (NIBIB); General...

Recruiting

Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma

Meningioma

United States
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center; Massachusetts General Hospital; City of Hope Medical... and other collaborators

Active, not recruiting

A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations

Lymphoma | Leukemia

United States
Hutchmed

Active, not recruiting

A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal, and Breast Cancer

Rectal Cancer | Advanced Solid Tumors | Metastatic Breast Cancer | Triple Negative Breast Cancer | Metastatic Colon Cancer | Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast Cancer

United States
Vaxxinity, Inc.

Recruiting

A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-313 in Healthy Participants

Migraine

Belgium
Hutchmed

Completed

Fruquintinib Renal Impairment Study

Renal Impairment

United States
argenx
Quintiles, Inc.

Completed

A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP

Primary Immune Thrombocytopenia

Austria, Belgium, France, Germany, Spain, Czechia, Hungary, Poland, Ukraine, United Kingdom
argenx

Active, not recruiting

A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). (ADVANCE+)

Primary Immune Thrombocytopenia

United States, Austria, Belgium, Bulgaria, Czechia, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Spain, Turkey, United Kingdom, Ukraine
Hutchmed

Completed

Fruquintinib Hepatic Impairment Study

Hepatic Impairment

United States
Otonomy, Inc.

Completed

OTO-413 in Subjects With Speech-in-Noise Hearing Impairment

Sensorineural Hearing Loss

United States
Wyeth is now a wholly owned subsidiary of Pfizer
Solvay Pharmaceuticals

Terminated

Study Evaluating Safety and Tolerability of Ascending Multiple Dose of SLV-313 in Schizophrenia Patients

Healthy
Seikagaku Corporation
Chiltern International Inc.

Completed

SI-613 Study for Knee Osteoarthritis

Osteoarthritis, Knee

United States
Johns Hopkins University

Terminated

Positron Emission Tomography (PET) Imaging of Glial Activation in Psychotic Disease States

Schizophrenia | Bipolar Disorder

United States
Kaken Pharmaceutical
Dow Pharmaceutical Sciences

Completed

A Study to Determine the Safety, Tolerability and Efficacy of KP-413 in Subjects With Atopic Dermatitis(AD)

Atopic Dermatitis

United States
M.D. Anderson Cancer Center

Active, not recruiting

A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas

Lymphomas | B-cell Lymphomas

United States
argenx

Completed

A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness. (ADAPT+)

Generalized Myasthenia Gravis

United States, Belgium, Canada, Czechia, Denmark, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Serbia
Otonomy, Inc.

Completed

OTO-313 in Subjects With Unilateral Subjective Tinnitus

Subjective Tinnitus

United States, United Kingdom, Germany, Poland
Otonomy, Inc.

Completed

OTO-313 in Subjects With Subjective Tinnitus

Tinnitus, Subjective

United States
argenx

Approved for marketing

Efgartigimod Expanded Access for Generalized Myasthenia Gravis

Generalized Myasthenia Gravis

United States
Chongqing Medical University

Unknown

Evaluation of C13 Breath Test for Upper Gastrointestinal Bleeding in Patients Who Need Double Antiplatelet After PCI

Acute Myocardial Infarction
Hutchison Medipharma Limited
Sun Yat-sen University; Fudan University

Completed

A Phase Ib Study of Fruquintinib in 3rd Line mCRC

Colorectal Cancer

China
Hutchison Medipharma Limited

Completed

A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors

Solid Tumor

China
Hutchison Medipharma Limited

Completed

Food Effect Study of Single Dose of Fruquintinib (HMPL-013) in Healthy Subjects

Food Effect of Fruquintinib in Health Subjects

China
Hutchison Medipharma Limited

Completed

A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion Of [14C] Fruquintinib

Healthy

China
argenx

Completed

IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers

Healthy Volunteers
Wyeth is now a wholly owned subsidiary of Pfizer
Solvay Pharmaceuticals

Terminated

Study Evaluating Multiple Ascending Dose in Schizophrenia Patients

Healthy
Happify Inc.

Completed

Digital Therapeutic for Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD)

Generalized Anxiety Disorder | Major Depressive Disorder

United States
Phoenicis Therapeutics

Terminated

A Double-blind, Randomized, Intra-subject Placebo-controlled, Multicenter, Multiple Dose Study, Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With Confirmed DDEB or RDEB Diagnosis With One or More Pathogenic Mutations in Exon 73 in the COL7A1 Gene

Epidermolysis Bullosa Dystrophica, Recessive | Epidermolysis Bullosa Dystrophica, Dominant

United States, Spain, France
argenx
Quintiles, Inc.

Completed

A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness

Myasthenia Gravis

Italy, United States, Belgium, Canada, Netherlands, Poland, Spain, Sweden

Search clinical trials for: hzVSF-v13

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations